Astellas Institute for Regenerative Medicine Sustainability Profile
Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas Pharma Inc., is a pioneering entity in the field of regenerative medicine, headquartered in the United States. Established in 2007, AIRM focuses on developing innovative cell therapies aimed at addressing unmet medical needs, particularly in the areas of oncology and rare diseases. With a commitment to advancing scientific research, AIRM has achieved significant milestones, including the development of unique cell-based therapies that leverage cutting-edge technology. The institute's core offerings include advanced cell therapy products that stand out for their potential to transform patient outcomes. Recognised for its contributions to the regenerative medicine landscape, AIRM continues to solidify its market position through strategic partnerships and a robust pipeline of therapeutic candidates, driving forward the future of healthcare.
DitchCarbon Score
How does Astellas Institute for Regenerative Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas Institute for Regenerative Medicine's score of 50 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astellas Institute for Regenerative Medicine, headquartered in the US, currently does not report specific carbon emissions data for the most recent year. The organisation's climate commitments and reduction initiatives are inherited from its parent company, Astellas Pharma Inc., at a cascade level of 2. As of now, there are no documented reduction targets or significant achievements in emissions reduction specific to Astellas Institute for Regenerative Medicine. The absence of emissions data and reduction initiatives suggests a need for further development in their climate strategy. The climate commitments and targets from Astellas Pharma Inc. may influence the subsidiary's future actions, but specific details on these initiatives are not provided. Overall, Astellas Institute for Regenerative Medicine is positioned within a broader corporate framework that may guide its environmental impact strategies moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Astellas Institute for Regenerative Medicine's Industry?
How Carbon Intensive is Astellas Institute for Regenerative Medicine's Location?
Astellas Institute for Regenerative Medicine's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Astellas Institute for Regenerative Medicine has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
